Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.
To learn more, read the full press release from Cynata Therapeutics, included below with permission Dr. Ross Macdonald, CEO of Cynata Therapeutics.
Cynata Announces Japanese Patent Office Decision to Grant Patent for Cymerus™ MSC Technology
Melbourne, Australia; 2 May 2016 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced that the Japanese Patent and Trademark Office has issued a Decision to Grant a patent covering certain aspects of its proprietary Cymerus™ mesenchymal stem cell (MSC) manufacturing technology. [Read more…]